Evidence map›Paper›PMID 39175037›Full record

ArticleEuropean journal of medical research2024

Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer.

Zhu Wen, Qinghua Li, Guangmo Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhu WenDepartment of Urology, The First People's Hospital of Hefei, Hefei, 230061, Anhui, China. urology_wen@163.com.
Qinghua LiDepartment of Urology, The First People's Hospital of Hefei, Hefei, 230061, Anhui, China.
Guangmo HuDepartment of Urology, The First People's Hospital of Hefei, Hefei, 230061, Anhui, China.

Funding

National Natural Science Foundation of China 82071637
6 · The paper itself

Abstract

Enzalutamide (Enz) is commonly utilized as the initial treatment strategy for advanced prostate cancer (PCa). However, a notable subset of patients may experience resistance to Enz, resulting in reduced effectiveness. Utilizing Gene Expression Omnibus (GEO) databases, we identified CBX2 as a crucial factor in mediating resistance to Enz, primarily due to its inhibitory effect on the P53 signaling pathway. Silencing of CBX2 using small interfering RNA (siRNA) led to elevated levels of P53 expression in LNCaP cells. This indicates that CBX2 may have a critical effect on PCa Enz resistance and could serve as a promising therapeutic target for individuals with Enz resistance.

Indexed as

BenzamidesComputational BiologyDrug Resistance, NeoplasmNitrilesPhenylthiohydantoinProstatic NeoplasmsCell Line, TumorGene Expression Regulation, NeoplasticHumansMalePolycomb Repressive Complex 1Signal TransductionTumor Suppressor Protein p53BenzamidesCBX2 protein, humanenzalutamideNitrilesPhenylthiohydantoinPolycomb Repressive Complex 1Tumor Suppressor Protein p53CBX2EnzalutamidePCaProstate cancerResistance

Identifiers

PMID39175037
PMCPMC11340159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.